Association between atherogenic index of plasma trajectories and non-alcoholic fatty liver disease in the elderly population

WU Xinri; CHEN Quan; ZHANG Caiqin; HONG Xin

doi:10.16462/j.cnki.zhjbkz.2025.04.005

Volume 29 Issue 4

Apr. 2025

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2025 > 29(4): 399-405

WU Xinri, CHEN Quan, ZHANG Caiqin, HONG Xin. Association between atherogenic index of plasma trajectories and non-alcoholic fatty liver disease in the elderly population[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(4): 399-405. doi: 10.16462/j.cnki.zhjbkz.2025.04.005

Citation:

WU Xinri, CHEN Quan, ZHANG Caiqin, HONG Xin. Association between atherogenic index of plasma trajectories and non-alcoholic fatty liver disease in the elderly population[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(4): 399-405. doi: 10.16462/j.cnki.zhjbkz.2025.04.005

Citation:

WU Xinri, CHEN Quan, ZHANG Caiqin, HONG Xin. Association between atherogenic index of plasma trajectories and non-alcoholic fatty liver disease in the elderly population[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2025, 29(4): 399-405. doi: 10.16462/j.cnki.zhjbkz.2025.04.005

PDF( 1364 KB)

Association between atherogenic index of plasma trajectories and non-alcoholic fatty liver disease in the elderly population

doi: 10.16462/j.cnki.zhjbkz.2025.04.005

WU Xinri^{1, 2},
CHEN Quan³,
ZHANG Caiqin^{1, 2},
HONG Xin^{1
,
,}

1.
Department of Non-communicable Chronic Disease Control and Prevention, Nanjing Center for Disease Control and Prevention Affiliated to Nanjing Medical University, Nanjing 210003, China
2.
Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, China
3.
Department of Education, Wuxi Second People′s Hospital, Wuxi 214002, China

Funds:

Jiangsu Provincial Health and Health Commission 2022 Medical Research Project M2022028

Research and Innovation Project of Nanjing Institute of Public Health, Nanjing Medical University NCX2301

More Information

Corresponding author: HONG Xin, E-mail: nj_hongxin@126.com
Received Date: 2024-10-30
Rev Recd Date: 2025-01-09
Publish Date: 2025-04-10

Abstract

Abstract

Objective To investigate the association between atherogenic index of plasma (AIP) trajectory and non-alcoholic fatty liver disease (NAFLD) in the elderly population. Methods A study cohort of 28 535 elderly people who met the inclusion criteria were selected from six years (2018-2023) of consecutive health examination data in Nanjing. The trajectory of AIP over the years from 2018 to 2021 by gender was constructed using the SAS Proc Traj program. The incidence of NAFLD in each trajectory group for male and female subjects were compared. A Cox regression model was used to analyze the association between distinct trajectory groups and the risk of NAFLD. Results Three AIP trajectory groups were identified for both males and females, namely the low-stable group, the moderate-stable group, and the high-stable group. The study revealed that the incidence of NAFLD was the highest in the high-stable group (29.44% in women and 14.35% in men). After adjusting for confounders such as age and BMI, etc., the risk of NAFLD incidence in the moderate-stable and high-stable AIP group was 1.824 times (95% CI: 1.514-2.196) and 2.323 times (95% CI: 1.815-2.972) that of the low-stable group in men, respectively, and 1.657 times (95% CI: 1.483-1.852) and 2.189 times (95% CI: 1.876-2.555) in women (all P<0.001). Conclusions A high AIP level is a risk factor for the development of NAFLD, and the risk of developing NAFLD increases with the elevation of AIP.
- Trajectories of atherogenic index of plasma,
- Non-alcoholic fatty liver disease,
- Elderly population,
- Cohort study

FullText(HTML)

References(23)

References

[1]	Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347. DOI: 10.1097/HEP.0000000000000004.
[2]	Wu YK, Zheng Q, Zou BY, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a Meta-analysis[J]. Hepatol Int, 2020, 14(2): 259-269. DOI: 10.1007/s12072-020-10023-3.
[3]	Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. DOI: 10.1016/S0140-6736(20)32511-3.
[4]	Cariou B. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: implications for treatment[J]. Diabetes Obes Metab, 2022, 24: 15-27. DOI: 10.1111/dom.14651.
[5]	Choudhary MK, Eräranta A, Koskela J, et al. Atherogenic index of plasma is related to arterial stiffness but not to blood pressure in normotensive and never-treated hypertensive subjects[J]. Blood Press, 2019, 28(3): 157-167. DOI: 10.1080/08037051.2019.1583060.
[6]	Ismaiel A, Ciobanu OS, Ismaiel M, et al. Atherogenic index of plasma in non-alcoholic fatty liver disease: systematic review and Meta-analysis[J]. Biomedicines, 2022, 10(9): 2101. DOI: 10.3390/biomedicines10092101.
[7]	Dong BY, Mao YQ, Li ZY, et al. The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study[J]. Lipids Health Dis, 2020, 19(1): 148. DOI: 10.1186/s12944-020-01319-2.
[8]	Liu J, Zhou LY, An Y, et al. The atherogenic index of plasma: a novel factor more closely related to non-alcoholic fatty liver disease than other lipid parameters in adults[J]. Front Nutr, 2022, 9: 954219. DOI: 10.3389/fnut.2022.954219.
[9]	Nguena Nguefack HL, Pagé MG, Katz J, et al. Trajectory modelling techniques useful to epidemiological research: a comparative narrative review of approaches[J]. Clin Epidemiol, 2020, 12: 1205-1222. DOI: 10.2147/CLEP.S265287.
[10]	Nagin DS, Jones BL, Elmer J. Recent advances in group-based trajectory modeling for clinical research[J]. Annu Rev Clin Psychol, 2024, 20(1): 285-305. DOI: 10.1146/annurev-clinpsy-081122-012416.
[11]	中华人民共和国国家卫生健康委员会. 国家卫生计生委关于印发《国家基本公共卫生服务规范(第三版)》的通知[EB/OL]. (2017-03-28)[2023-10-10]. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=d20c37e23e1f4c7db7b8e25f34473e1b.
[12]	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版)[J]. 中华肝脏病杂志, 2018, 26(3): 195-203. DOI: 10.3760/cma.j.issn.1007-3418.2018.03.008. Liver Disease Branch of Chinese Medical Association, Expert Committee on Fatty Liver Disease of Chinese Physician Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update[J]. Chin J Hepatol, 2018, 26(3): 195-203. DOI: 10.3760/cma.j.issn.1007-3418.2018.03.008.
[13]	Chen Y, Lu C, Ju HN, et al. Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017-2018[J]. Front Endocrinol, 2024, 15: 1405828. DOI: 10.3389/fendo.2024.1405828.
[14]	中华医学会老年医学分会, 中国医疗保健国际交流促进会高血压病分会. 老年高血压特点及临床诊治流程专家共识(2024)[J]. 中华老年医学杂志, 2024, 43(3): 257-268. DOI: 10.3760/cma.j.issn.0254-9026.2024.03.001. Geriatrics Branch of Chinese Medical Association, Hypertension Branch of China International Exchange and Promotion Association for Medical and Health Care. Consensus on characteristics and clinical diagnosis and treatment process of hypertension in the elderly(2024)[J]. Chin J Geriatr, 2024, 43(3): 257-268. DOI: 10.3760/cma.j.issn.0254-9026.2024.03.001.
[15]	中国老年型糖尿病防治临床指南编写组, 中国老年医学学会老年内分泌代谢分会, 中国老年保健医学研究会老年内分泌与代谢分会, 等. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中华内科杂志, 2022, 61(1): 12-50. DOI: 10.3760/cma.j.cn112138-20211027-00751. Writing Group for the Clinical Guidelines for Prevention and Treatment of Type2 Diabetes in Elderly People in China, Geriatric Endocrinology and Metabolism Branch of Chinese Geriatrics Society, Geriatric Endocrinology and Metabolism Branch of Chinese Society of Geriatric Medicine, et al. Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)[J]. Chin J Intern Med, 2022, 61(1): 12-50. DOI: 10.3760/cma.j.cn112138-20211027-00751.
[16]	中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10): 937-950. DOI: 10.3969/j.issn.1000-3614.2016.10.001. Joint Committee for the Revision of Guidelines for the Prevention and Treatment of Dyslipidemia in Adults in China. Guidelines for the prevention and treatment of dyslipidemia in adults in China (2016 revised edition). Chin Circ J, 2016, 31(10): 937-950. DOI: 10.3969/j.issn.1000-3614.2016.10.001.
[17]	Ziolkowska S, Binienda A, Jabłkowski M, et al. The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease[J]. Int J Mol Sci, 2021, 22(20): 11128. DOI: 10.3390/ijms222011128.
[18]	Ziamanesh F, Mohammadi M, Ebrahimpour S, et al. Unraveling the link between insulin resistance and non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): a narrative review[J]. J Diabetes Metab Disord, 2023, 22(2): 1083-1094. DOI: 10.1007/s40200-023-01293-3.
[19]	Palma R, Pronio A, Romeo M, et al. The role of insulin resistance in fueling NAFLD pathogenesis: from molecular mechanisms to clinical implications[J]. J Clin Med, 2022, 11(13): 3649. DOI: 10.3390/jcm11133649.
[20]	Li KM, Li J, Cheng XY, et al. Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants[J]. Front Endocrinol, 2022, 13: 969783. DOI: 10.3389/fendo.2022.969783.
[21]	Lin J, Li H, Wan Q. A cross-sectional study of the correlation between the atherogenic index of plasma and nonalcoholic fatty liver disease in patients with type 2 diabetes[J]. Diabetes Metab Syndr Obes, 2022, 15: 2227-2234. DOI: 10.2147/DMSO.S375300.
[22]	Nagral A, Bangar M, Menezes S, et al. Gender differences in nonalcoholic fatty liver disease[J]. Euroasian J Hepatogastroenterol, 2022, 12: S19-S25. DOI: 10.5005/jp-journals-10018-1370.
[23]	DiStefano JK. NAFLD and NASH in postmenopausal women: implications for diagnosis and treatment[J]. Endocrinology, 2020, 161(10): bqaa134. DOI: 10.1210/endocr/bqaa134.